PW Medtech Group Limited — Capital/Financing Update 2017

Dec 29, 2017

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED 普 華 和 順 集 團 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

DELAY IN THE CLOSING UNDER THE SHARE EXCHANGE AGREEMENT

Reference is made to the circular of PW Medtech Group Limited (the ‘‘Company’’) dated November 14, 2017 (the ‘‘Circular’’) and the poll results announcement dated December 1, 2017 in relation to the proposed subscription for CBPO Shares in consideration of the Disposal Business. Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Circular.

As disclosed in the Circular, the Closing was scheduled to take place within five business days after the last condition precedent having been satisfied or waived, or a later date as may be agreed by the parties in writing, which was expected to be no later than December 31, 2017.

Due to holidays in December in both Hong Kong and the United States, the parties consider that there may be a slight delay in the Closing for fulfilling certain administrative procedures. Accordingly, the Company and CBPO entered into an amendment to the Share Exchange Agreement on December 29, 2017 to reflect such change.

The parties currently expect the Closing to take place no later than January 5, 2018 and an announcement regarding the update on the Closing will be made as soon as practicable.

By Order of the Board PW Medtech Group Limited Yue’e Zhang Chairman

Hong Kong, December 29, 2017

As at the date of this announcement, the Board comprises two executive Directors, namely, Ms. Yue’e Zhang and Mr. Jiang Liwei; one non-executive Director, namely Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Zhang Xingdong, Mr. Chen Geng and Mr. Wang Xiaogang.